Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of StemCell Institute Inc.. A complete text table follows the diagram.
The company generated ¥1.42bn of sales while expanding its regenerative-medicine platform.
Swipe to explore
Every category amount is a reported EDINET XBRL fact. Nodes described as arithmetic bridges are calculated residuals and do not imply a separately reported filing line.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Reported sales | 1 | 1.4B | 100.0% of reported total |
| Regenerative-medicine services | 2 | 1.4B | Reported six-month total · ¥1.4B |
| Operating profit | 3 | 130M | 9.2% operating margin |
| Operating costs & expenses | 3 | 1.3B | Arithmetic residual to reported operating profit |
| Profit before tax | 4 | 137M | Reported pretax result |
| StemCell Institute scales cell-processing operations | 3 | 6.8M | Sales reached ¥1.42bn with ¥130.4m operating income as cell-processing services supported development work. |
| Net profit attributable to owners | 5 | 84.9M | Reported parent-company result |
| Tax, attribution & other | 5 | 52.3M | Arithmetic bridge to owners' profit |
| From | To | Value |
|---|---|---|
| Reported sales | Regenerative-medicine services | 1.4B |
| Regenerative-medicine services | Operating profit | 130M |
| Regenerative-medicine services | Operating costs & expenses | 1.3B |
| Operating profit | Profit before tax | 130M |
| StemCell Institute scales cell-processing operations | Profit before tax | 6.8M |
| Profit before tax | Net profit attributable to owners | 84.9M |
| Profit before tax | Tax, attribution & other | 52.3M |